CD206 antibody | MR5D3
Rat anti Mouse CD206 antibody, clone MR5D3 (MCA2235) used for the evaluation of mannose expression by primary microglia from wild type and IL-1 knockout mice by western blotting of isolated microglial lysates.
Image caption:
Western blot analysis to identify the type of activation of adult primary microglial cells from wild-type and IL-1 KO mice stimulated by vehicle, IFNγ or IL-4 with or without IL-1β. (A) Representative western blotting data of primary MG produced from wild-type (wild) and IL-1 KO mice exposed for 24 hours to vehicle, IFNγ or IL-4 with or without IL-1β. Each lane expected to CD206 blotting applied 8 μg of reduced samples. Non-reduced samples (5 μg) were applied to detect CD206. Densitometric analysis of STAT1 (B), COX2 (C), iNOS (D), Ym1 (E), Arg-1 (F) and CD206 (G) (n = 3 each group). (B) STAT1 level is increased by exposure of cells to IFNγ, but not to IL-4. The level is not influenced by co-treatment of cells with IL-1β. (C) The COX2 level is increased by exposure of cells to IL-1β but not to IFNγ or IL-4 alone. Co-treatment with IL-1β and IL-4 tends to increase the COX2 level synergistically. (D) While the iNOS level is not increased significantly by exposure of cells to IFNγ or IL-4, the level increased synergistically in response to co-treatment with IFNγ and IL-1β. (D) The level of Ym1 is increased by exposure of cells to IL-4 and further increased by co-treatment with IL-1β. (E) The Arg-1 level is also increased by exposure of cells to IL-4 and further increased by co-treatment with IL-1β. (G) The CD206 level is increased slightly by exposure of cells to IL-4, but not with co-treatment with IL-4 and IL-1β. Data are expressed as mean ± SD (n = 3). *: P < 0.05, **: P < 0.01, ***: P < 0.001 compared to the vehicle-treated group without IL-1β for each genotype (One-way ANOVA followed by Dunnett post-hoc test). ANOVA, analysis of variance; arg-1, arginase 1; COX2, cyclooxygenase 2; iNOS, inducible NO synthase.
From: Sato A, Ohtaki H, Tsumuraya T, Song D, Ohara K, Asano M, Iwakura Y, Atsumi T, Shioda S. Interleukin-1 participates in the classical and alternative activation of microglia/macrophages after spinal cord injury.
J Neuroinflammation. 2012 Apr 7;9:65.
Rat anti Mouse CD206 antibody, clone MR5D3 (MCA2235) used for the evaluation of mannose expression by primary microglia from wild type and IL-1 knockout mice by western blotting of isolated microglial lysates.
Image caption:
Western blot analysis to determine type of activation of adult primary microglial cells produced from wild-type and IL-1 KO mice stimulated with IL-4, IL-13 or IL-4/IL-13 with or without IL-1β. (A) Representative western blotting data of primary microglial cells produced from wild-type (wild) and IL-1 KO mice and exposed for 24 hours to IL-4, IL-13 or IL-4 plus IL-13 (IL-4/IL-13) with or without IL-1β. Each lane expected to CD206 blotting were applied 7 μg of reduced samples. Non-reduced samples (5 μg) were applied to detect CD206. Densitometric analysis of COX2 (B), Ym1 (C), Arg-1 (D) and CD206 (E) (n = 3 each group). (B) COX2 levels are increased by exposure of cells to IL-1β and are not influenced by IL-4 or IL-13 alone. The COX2 level was slightly enhanced by IL-1β and IL-4 co-treatment. (C) Ym1 levels are increased by exposure of cells to IL-4 and IL-4/Il-13 and are synergistically increased by co-treatment with IL-1β. However, only a low level of Ym1 is seen upon exposure of cells to IL-13, and is significantly less than that seen in response to exposure of cells to IL-4. (D) Arg-1 shows similar levels in response to exposure to IL-4 and IL-4/IL-13; these are synergistically increased by co-treatment with IL-1β. However, low levels of Arg-1 are seen for exposure of cells to IL-13. (G) CD206 was detected in response to exposure of cells to both IL-4 and IL-4/IL-13 with or without IL-1β; however, CD206 levels in IL-13-exposed samples were lower than those seen with the other treatments. Data are expressed as mean ± SD (n = 3). *: P < 0.05, **: P < 0.01, ***: P < 0.001 compared with the IL-4-treated group without IL-1β for each genotype (one-way ANOVA followed by Dunnett post-hoc test). ANOVA, analysis of variance; arg-1, arginase 1; COX 2, cyclooxygenase 2.
From: Sato A, Ohtaki H, Tsumuraya T, Song D, Ohara K, Asano M, Iwakura Y, Atsumi T, Shioda S. Interleukin-1 participates in the classical and alternative activation of microglia/macrophages after spinal cord injury.
J Neuroinflammation. 2012 Apr 7;9:65.
Rat anti Mouse CD206 antibody, clone MR5D3 (MCA2235) used for the detection of mannose receptor expressing macrophages in hind limbs of control and ischemia induced mice by immunofluorescence.
Image caption:
Increased accumulation of repair-associated macrophages surrounding collaterals in ischemic hind limbs is PAR2-dependent. (A) Stainings of CD206-positive macrophages (green) and SMA-positive vessels (red) in non-ischemic (control) and ischemic (ligated) hind limbs of WT, PAR1-/- and PAR2-/- mice are shown. Nuclei were visualized with DAPI (blue). Arrows indicate single macrophages in the non-ischemic adductor. Quantification of the average number of repair-associated macrophages per vessel is indicated on the right. (B) Correlation between the number of CD206-positive macrophages in the ischemic tissues and the expression of CD11b and (C) CD115 on monocytes. ** p<0.01, *** p<0.001.
From: van den Hengel LG, Hellingman AA, Nossent AY, van Oeveren-Rietdijk AM, de Vries MR, Spek CA, et al. (2013) Protease-Activated Receptor (PAR)2, but Not PAR1, Is Involved in Collateral Formation and Anti-Inflammatory Monocyte Polarization in a Mouse Hind Limb Ischemia Model.
PLoS ONE 8(4): e61923.
Rat anti Mouse CD206 antibody, clone MR5D3 (MCA2235) used for the evaluation of alternative macrophage activation in the lungs of fibrotic IFNγ knockout and wild type mice by flow cytometry on isolated cells.
Image caption:
Elevated levels of alternative macrophage activation are observed in lung of fibrotic IFNγR-/- C57Bl/6 mice. 8–12 week old C57Bl/6 IFNγR-/- mice were intranasally infected with 1x105 pfu MHV68 (WT or M1st) and sacrificed at indicated times post infection (n = 3–4 mice/group at each timepoint). Whole lungs were harvested and assessed for macrophage population and phenotype. (A-B) Absolute number of alveolar and interstitial macrophages were quantified and assessed for alternative activation using RELMα and CD206 expression.
From: O'Flaherty BM, Matar CG, Wakeman BS, Garcia A, Wilke CA, Courtney CL, et al. (2015) CD8+ T Cell Response to Gammaherpesvirus Infection Mediates Inflammation and Fibrosis in Interferon Gamma Receptor-Deficient Mice.
PLoS ONE 10(8): e0135719.
Rat anti Mouse CD206 antiboddy, clone MR5D3 (MCA2235GA) used for the illustration of mannose receptor expressing cells in murine liver by immunofluorescence.
Image caption:
Immunohistochemical analysis of expression of FPR1 in human and mouse liver tissue.
Liver sections were fixed with cold acetone for 10 min, washed in PBS and incubated overnight at 4°C with polyclonal rabbit anti-FPR1 (1:200), followed by Alexa Fluor®-488 goat anti-rabbit (1:1000). Intense FPR1 staining can be observed along the sinusoids in mouse liver (A), while in human liver the staining was more evenly localized to both LSECs and Heps (B). Double staining was performed using polyclonal rabbit anti-FPR1, rat anti-mouse CD206, and goat anti-human CD206, followed by Alexa Fluor®-488 and Alexa Fluor®-594 secondary antibodies, respectively.
From: Citation: Øie CI, Snapkov I, Elvevold K, Sveinbjørnsson B, Smedsrød B (2016)
FITC Conjugation Markedly Enhances Hepatic Clearance of N-Formyl Peptides.
PLoS ONE 11(8): e0160602. doi:10.1371/journal.pone.0160602
Rat anti Mouse CD206 antibody, clone MR5D3 (MCA2235) used for the evaluation of CD206 expression on BV-2 microglial cells following cytokine treatment in vitro by immunofluorescence.
Image caption:
cPLA2α is not involved in the induction of the BV-2 cells towards M2 phenotype induced by IL-4 + IL-10. A representative double-immunofluorescence staining of cPLA2α (green) and CD206 (red) in the unstimulated or stimulated BV-2 cells with IL-4 (20 ng/ml) + IL-10 (20 ng/ml) for 24 h in the absence or presence of AS or SE. DAPI staining shows cell nuclei. Scale bars = 100μm. a The intensity of CD206 or cPLA2α were quantitated and expressed in the bar graph as arbitrary units. The bar graphs are the mean ± SE from three independent experiments. b A representative immunoblot analysis of arginase 1 protein expression in the cells treated as in a. The intensity of each Arg1 band after quantification by densitometry was divided by the intensity of each calreticulin band and expressed as arbitrary units. The bar graphs are the mean ± SE from three independent experiments (***p<0.0001, n.s. not significant).
From: Malada-Edelstein YF, Hadad N, Levy R.
Regulatory role of cytosolic phospholipase A(2) alpha in the induction of CD40 in microglia.
J Neuroinflammation. 2017 Feb 10;14(1):33.
Rat anti Mouse CD206:Alexa Fluor® 488
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
Rat anti Mouse CD206:Alexa Fluor® 647
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
Rat anti Mouse CD206:Biotin
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
Rat anti Mouse CD206:FITC
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
Rat anti Mouse CD206:Low Endotoxin
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
Rat anti Mouse CD206:Pacific Blue®
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
Rat anti Mouse CD206
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
Rat anti Mouse CD206:RPE
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
Rat anti Mouse CD206:RPE-Alexa Fluor® 750
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
Rat anti Mouse CD206:Alexa Fluor® 700
CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a 175kD type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells, and in vitro derived dendritic cells.
- Product Type
- Monoclonal Antibody
- Clone
- MR5D3
- Isotype
- IgG2a
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| MCA2235A488T | F* | 25 Tests/0.25ml |
|
|
| MCA2235A488 | F* | 100 Tests/1ml |
|
|
| MCA2235A647T | F* | 25 Tests/0.25ml |
|
|
| MCA2235A647 | F* | 100 Tests/1ml |
|
|
| MCA2235BT | F* | 25 µg |
|
|
| MCA2235B | F* | 0.1 mg |
|
|
| MCA2235FT | F* | 25 µg |
|
|
| MCA2235FA | F* | 50 µg |
|
|
| MCA2235F | F* | 0.1 mg |
|
|
| MCA2235FB | F* | 0.5 mg |
|
|
| MCA2235EL | C F* IF IP | 0.5 mg |
|
|
| MCA2235PB | F* | 100 Tests/1ml |
|
|
| MCA2235T | C F* IF IP | 25 µg |
|
|
| MCA2235GA | C F* IF IP | 0.1 mg |
|
|
| MCA2235 | C F* IF IP | 0.25 mg |
|
|
| MCA2235PET | F* | 25 Tests |
|
|
| MCA2235PE | F* | 100 Tests |
|
|
| MCA2235P750 | F* | 100 Tests |
|
|
| MCA2235A700 | F* | 100 Tests/1ml |
|
Rat anti mouse CD206 antibody, clone MR5D3 recognizes the mouse mannose receptor, a ~175 kDa type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells and in vitro derived dendritic cells (Zamze et al. 2002).
The mannose receptor, CD206, is composed of a N-terminal cysteine-rich domain, a fibronectin type II domain, eight tandemly arranged C-type lectin domains (CTLD), a transmembrane domain, and a cytoplasmic domain. The terminal cysteine-rich domain binds sulfated sugars, and the CTLD recognizes carbohydrates terminating in mannose, fucose and N-acetylglucosamine, all sugars found on microorganisms and on some endogenous proteins (Su et al. 2005).
Rat anti mouse CD206 antibody, clone MR5D3 has been reported to be non-inhibitory for the binding of the mannose receptor to carbohydrate ligands (Zamze et al. 2002). Clone MR5D3 has also been shown to work in Western Blot (Martinez-Pomares et al. 2003 and Su et al. 2005).
The mannose receptor, CD206, is composed of a N-terminal cysteine-rich domain, a fibronectin type II domain, eight tandemly arranged C-type lectin domains (CTLD), a transmembrane domain, and a cytoplasmic domain. The terminal cysteine-rich domain binds sulfated sugars, and the CTLD recognizes carbohydrates terminating in mannose, fucose and N-acetylglucosamine, all sugars found on microorganisms and on some endogenous proteins (Su et al. 2005).
Rat anti mouse CD206 antibody, clone MR5D3 has been reported to be non-inhibitory for the binding of the mannose receptor to carbohydrate ligands (Zamze et al. 2002). Clone MR5D3 has also been shown to work in Western Blot (Martinez-Pomares et al. 2003 and Su et al. 2005).
Product Details
- Target Species
- Mouse
- Product Form
- Purified IgG conjugated to Alexa Fluor® 488 - liquid
- Product Form
- Purified IgG conjugated to Alexa Fluor® 647 - liquid
- Product Form
- Purified IgG conjugated to Biotin - liquid
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to Pacific Blue - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Pack Size: 25 TestsPurified IgG conjugated to R. Phycoerythrin (RPE) - lyophilisedPack Size: 100 TestsPurified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Product Form
- Purified IgG conjugated to RPE-Alexa Fluor 750 - lyophilized
- Product Form
- Purified IgG conjugated to Alexa Fluor® 700 - liquid
- Reconstitution
- Pack Size: 25 TestsReconstitute with 0.25 ml distilled waterPack Size: 100 TestsReconstitute with 1 ml distilled water
- Reconstitution
- Reconstitute with 1.0 ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. - Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
- None Present
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Carrier Free
- Yes
- Carrier Free
- Yes
- Immunogen
- Chimaeric CRD4-7-Fc protein
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Pack Size: 25 µg, 50 µg, 0.1 mgIgG concentration 0.1 mg/mlPack Size: 0.5 mgIgG concentration 0.5 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Fusion Partners
- Spleen cells from immunised Fischer rats were fused with cells of the Y3 myeloma cell line
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at -20oC only.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Pack Size: 25 TestsPrior to reconstitution store at +4oC.
After reconstitution store at +4oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.Pack Size: 100 TestsStore at +4oC.
DO NOT FREEZE
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC.
After reconstitution store at +4oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 12 months from date of reconstitution.
- Guarantee
- 12 months from date of reconstitution
- Guarantee
- 18 months from date of despatch
More Information
- UniProt
- Q61830 Related reagents
- Entrez Gene
- Mrc1 Related reagents
- GO Terms
- GO:0016021 integral to membrane
- GO:0004888 transmembrane receptor activity
- GO:0005537 mannose binding
- GO:0006897 endocytosis
- GO:0009986 cell surface
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Regulatory
- For research purposes only
Applications of CD206 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry 1 | Neat | ||
| Flow Cytometry 1 | Neat | ||
| Flow Cytometry 1 | Neat | 1/10 | |
| Flow Cytometry 1 | neat | Neat Pack Size: 25 µg, 0.1 mg 1/10 Pack Size: 0.5 mg |
|
| Flow Cytometry 1 | |||
| Immunofluorescence | |||
| Immunohistology - Frozen | |||
| Immunoprecipitation | |||
| Flow Cytometry 1 | Neat | ||
| Flow Cytometry 1 | 1/10 | 1/20 | |
| Immunofluorescence | |||
| Immunohistology - Frozen | |||
| Immunoprecipitation | |||
| Flow Cytometry 1 | Neat | ||
| Flow Cytometry 1 | Neat | ||
| Flow Cytometry 1 | Neat |
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilization. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1 CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cell in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cell in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B) - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B).
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Rat IgG2a Negative Control:Alexa Fluor® 488 | MCA1212A488 | F | 100 Tests/1ml |
|
|
| Rat IgG2a Negative Control:Alexa Fluor® 647 | MCA1212A647 | F | 100 Tests/1ml |
|
|
| Rat IgG2a Negative Control:FITC | MCA1212F | F | 100 Tests |
|
|
| Rat IgG2a Negative Control:Low Endotoxin | MCA1212EL | F | 0.5 mg |
|
|
| Rat IgG2a Negative Control:Pacific Blue® | MCA1212PB | F | 100 Tests/1ml |
|
|
| Rat IgG2a Negative Control | MCA1212 | E F | 1 ml |
|
|
| Rat IgG2a Negative Control:RPE | MCA1212PE | F | 100 Tests |
|
|
| Rat IgG2a Negative Control:Alexa Fluor® 700 | MCA1212A700 | F | 100 Tests/1ml |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
Application Based External Images
Flow Cytometry
Immunofluorescence
Immunohistology - Frozen
Western Blotting
Product Specific References
References for CD206 antibody
-
Martinez-Pomares, L. et al. (2003) Analysis of mannose receptor regulation by IL-4, IL-10, and proteolytic processing using novel monoclonal antibodies.
J Leukoc Biol. 73 (5): 604-13. -
Zamze, S. et al. (2002) Recognition of bacterial capsular polysaccharides and lipopolysaccharides by the macrophage mannose receptor.
J Biol Chem. 277 (44): 41613-23. -
Hassan, M.F. et al. (2006) The Schistosoma mansoni hepatic egg granuloma provides a favorable microenvironment for sustained growth of Leishmania donovani.
Am J Pathol. 169: 943-53. -
Hardison, S.E. et al. (2010) Interleukin-17 Is Not Required for Classical Macrophage Activation in a Pulmonary Mouse Model of Cryptococcus neoformans Infection.
Infect Immun. 78: 5341-51. -
Geier, H. & Celli, J. (2011) Phagocytic receptors dictate phagosomal escape and intracellular proliferation of Francisella tularensis.
Infect Immun. 79 (6): 2204-14. -
Bacci, M. et al. (2009) Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease.
Am J Pathol. 175: 547-56. -
Chavele, K.M. et al. (2010) Mannose receptor interacts with Fc receptors and is critical for the development of crescentic glomerulonephritis in mice.
J Clin Invest. 120: 1469-78. -
deSchoolmeester, M.L. et al. (2009) The mannose receptor binds Trichuris muris excretory/secretory proteins but is not essential for protective immunity.
Immunology 126: 246-55. -
Devey, L. et al. (2009) Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism.
Mol Ther. 17: 65-72. -
Dewals, B.G. et al. (2010) IL-4Ralpha-independent expression of mannose receptor and Ym1 by macrophages depends on their IL-10 responsiveness.
PLoS Negl Trop Dis. 4 (5): e689. -
Hardison, S.E. et al. (2010) Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection.
Am J Pathol. 176: 774-85. -
Hawkes, C.A. et al. (2009) Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy.
Proc Natl Acad Sci USA106: 1261-6. -
Zehner, M. et al. (2011) Mannose receptor polyubiquitination regulates endosomal recruitment of p97 and cytosolic antigen translocation for cross-presentation.
Proc Natl Acad Sci USA 108: 9933-8. -
Famulski, K.S. et al. (2010) Alternative macrophage activation-associated transcripts in T-cell-mediated rejection of mouse kidney allografts.
Am J Transplant 10 (3): 490-7. -
Takagi, H. et al. (2009) Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages.
Glycobiology 19: 258-66. -
Deepe, G.S. Jr. & Buesing, W.R. (2011) Deciphering the Pathways of Death of Histoplasma capsulatum-Infected Macrophages: Implications for the Immunopathogenesis of Early Infection.
J Immunol. 188: 334-44. -
Schneider, D. et al. (2012) Neonatal rhinovirus infection induces mucous metaplasia and airways hyperresponsiveness.
J Immunol. 188 (6): 2894-904. -
Kondo, Y. et al. (2011) Macrophages counteract demyelination in a mouse model of globoid cell leukodystrophy.
J Neurosci. 31: 3610-24. -
Joyce, K.L. et al. (2012) Using eggs from Schistosoma mansoni as an in vivo model of helminth-induced lung inflammation.
J Vis Exp. Jun 5 (64): e3905. -
Su, Y. et al. (2005) Glycosylation influences the lectin activities of the macrophage mannose receptor.
J Biol Chem. 280: 32811-20. -
Verheijden, S. et al. (2015) Identification of a chronic non-neurodegenerative microglia activation state in a mouse model of peroxisomal β-oxidation deficiency.
Glia. 63 (9): 1606-20. -
O'Flaherty, B.M. et al. (2015) CD8+ T Cell Response to Gammaherpesvirus Infection Mediates Inflammation and Fibrosis in Interferon Gamma Receptor-Deficient Mice.
PLoS One. 10 (8): e0135719. -
Eßlinger M et al. (2016) Schizophrenia associated sensory gating deficits develop after adolescent microglia activation.
Brain Behav Immun. May 25. pii: S0889-1591(16): 30139-8. [Epub ahead of print] -
Øie, C.I. et al. (2016) FITC Conjugation Markedly Enhances Hepatic Clearance of N-Formyl Peptides.
PLoS One. 11 (8): e0160602. -
Manning, C.N. et al. (2015) Adipose-derived mesenchymal stromal cells modulate tendon fibroblast responses to macrophage-induced inflammation in vitro.
Stem Cell Res Ther. 6: 74. -
Malada-Edelstein, Y.F. et al. (2017) Regulatory role of cytosolic phospholipase A2 alpha in the induction of CD40 in microglia.
J Neuroinflammation. 14 (1): 33. -
Braune, J. et al. (2017) IL-6 Regulates M2 Polarization and Local Proliferation of Adipose Tissue Macrophages in Obesity.
J Immunol. Feb 13. pii: 1600476. [Epub ahead of print] -
Bongiorno, E.K. et al. (2017) Type 1 Immune Mechanisms Driven by the Response to Infection with Attenuated Rabies Virus Result in Changes in the Immune Bias of the Tumor Microenvironment and Necrosis of Mouse GL261 Brain Tumors.
J Immunol. May 1. pii: 1601444. [Epub ahead of print] -
Litvack ML et al. (2016) Alveolar-like Stem Cell-derived Myb(-) Macrophages Promote Recovery and Survival in Airway Disease.
Am J Respir Crit Care Med. 193 (11): 1219-29. -
Sameshima, A. et al. (2015) Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity.
J Endocrinol. 227 (1): 25-36. -
Eskilsson, A. et al. (2014) Distribution of microsomal prostaglandin E synthase-1 in the mouse brain.
J Comp Neurol. 522 (14): 3229-44. -
Hosono, K. et al. (2016) Signaling of Prostaglandin E Receptors, EP3 and EP4 Facilitates Wound Healing and Lymphangiogenesis with Enhanced Recruitment of M2 Macrophages in Mice.
PLoS One. 11 (10): e0162532. -
Han, Y.H. et al. (2019) A maresin 1/RORα/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis.
J Clin Invest. 130. pii: 124219
Our CD206 (MR5D3) Antibody has been referenced in >70 publications*
*Based on February 2018 data from CiteAb's antibody search engine.
